Cutaneous Melanoma — Trials

Cutaneous Melanoma — Trials · CancerIndex

Clinical trials

Registered studies

241 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 78
Recruiting: 39
Ph III recruiting: 3
Growth YoY: —
Industry share: 27%
Top sponsor: National Cancer Institute (NCI)
Termination share: 36.1%
Trials / 1,000 deaths: 9.3 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (42)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01274338	Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery	active not recruiting	Phase 3	1,673	National Cancer Institute (NCI)NIH	2	Sep 8, 2026	clinicaltrials
NCT02339571	A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma	active not recruiting	Phase 2 / Phase 3	600	National Cancer Institute (NCI)NIH	1	Aug 28, 2026